FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 357 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR For Advanced Prostate Cancer, Radiopharmaceutical Improves Survival June 29, 2021 BRCA Gene Testing: Risks, Benefits, Costs, and Coverage May 10, 2021 Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for... December 9, 2020 FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... July 19, 2024 Load more HOT NEWS Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower... How repurposing a drug in a COVID-19 trial could benefit people...
